DE69323213D1 - Kombination eines Hemmers der Cholesterin-Biosynthese und eines beta-laktamischem Hemmers der Cholesterinabsorption - Google Patents

Kombination eines Hemmers der Cholesterin-Biosynthese und eines beta-laktamischem Hemmers der Cholesterinabsorption

Info

Publication number
DE69323213D1
DE69323213D1 DE69323213T DE69323213T DE69323213D1 DE 69323213 D1 DE69323213 D1 DE 69323213D1 DE 69323213 T DE69323213 T DE 69323213T DE 69323213 T DE69323213 T DE 69323213T DE 69323213 D1 DE69323213 D1 DE 69323213D1
Authority
DE
Germany
Prior art keywords
inhibitor
cholesterol
pct
beta
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69323213T
Other languages
English (en)
Other versions
DE69323213T2 (de
Inventor
Harry Davis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme Corp
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of DE69323213D1 publication Critical patent/DE69323213D1/de
Publication of DE69323213T2 publication Critical patent/DE69323213T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
DE69323213T 1992-12-23 1993-12-21 Kombination eines Hemmers der Cholesterin-Biosynthese und eines beta-laktamischem Hemmers der Cholesterinabsorption Expired - Lifetime DE69323213T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99548892A 1992-12-23 1992-12-23
PCT/US1993/012291 WO1994014433A1 (en) 1992-12-23 1993-12-21 COMBINATION OF A CHOLESTEROL BIOSYNTHESIS INHIBITOR AND A β-LACTAM CHOLESTEROL ABSORPTION INHIBITOR

Publications (2)

Publication Number Publication Date
DE69323213D1 true DE69323213D1 (de) 1999-03-04
DE69323213T2 DE69323213T2 (de) 1999-07-08

Family

ID=25541876

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69323213T Expired - Lifetime DE69323213T2 (de) 1992-12-23 1993-12-21 Kombination eines Hemmers der Cholesterin-Biosynthese und eines beta-laktamischem Hemmers der Cholesterinabsorption

Country Status (32)

Country Link
US (1) US5661145A (de)
EP (1) EP0675714B1 (de)
JP (1) JP3992728B2 (de)
KR (1) KR100306936B1 (de)
CN (1) CN1090479C (de)
AT (1) ATE175872T1 (de)
AU (1) AU680864B2 (de)
CA (1) CA2152351C (de)
CZ (1) CZ287125B6 (de)
DE (1) DE69323213T2 (de)
DK (1) DK0675714T3 (de)
EE (1) EE03383B1 (de)
ES (1) ES2128552T3 (de)
FI (1) FI952916A0 (de)
GR (1) GR3029405T3 (de)
HR (1) HRP931515B1 (de)
HU (1) HU221724B1 (de)
IL (1) IL108112A (de)
LT (1) LT3300B (de)
LV (1) LV10919B (de)
MX (1) MX9308053A (de)
MY (1) MY109538A (de)
NO (1) NO311325B1 (de)
NZ (1) NZ259790A (de)
PL (1) PL174128B1 (de)
SG (1) SG45147A1 (de)
SI (1) SI9300677A (de)
SK (1) SK281173B6 (de)
TW (1) TW319698B (de)
WO (1) WO1994014433A1 (de)
YU (1) YU49060B (de)
ZA (1) ZA939552B (de)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5631365A (en) 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
CA2200436A1 (en) * 1994-09-20 1996-04-04 Pfizer Inc. Combination therapy for hypercholesterolemia
US5633246A (en) * 1994-11-18 1997-05-27 Schering Corporation Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
US5624920A (en) * 1994-11-18 1997-04-29 Schering Corporation Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
US5656624A (en) * 1994-12-21 1997-08-12 Schering Corporation 4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents
WO1997016184A1 (en) 1995-11-02 1997-05-09 Warner-Lambert Company Method and pharmaceutical composition for regulating lipid concentration
US20030153541A1 (en) * 1997-10-31 2003-08-14 Robert Dudley Novel anticholesterol compositions and method for using same
SI20109A (sl) * 1998-12-16 2000-06-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Stabilna farmacevtska formulacija
US6593078B1 (en) 1999-04-16 2003-07-15 Schering Corporation Use of azetidinone compounds
EP1192963A4 (de) * 2000-04-05 2004-08-25 Toray Industries Adsorbentien für proteine der gruppe high mobility protein und säule zum reinigen von körperflüssigkeiten
US6979462B1 (en) * 2000-10-03 2005-12-27 Mutual Pharmaceutical Co., Inc. Stabilization of solid drug formulations
US6584357B1 (en) * 2000-10-17 2003-06-24 Sony Corporation Method and system for forming an acoustic signal from neural timing difference data
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
EP1911462A3 (de) 2001-01-26 2011-11-30 Schering Corporation Zusammensetzungen enthaltend einen Sterolabsorptionshemmer
CN101297969B (zh) * 2001-01-26 2011-03-09 先灵公司 过氧化物酶体增殖物激活受体(ppar)活化剂和甾醇吸收抑制剂的组合药
KR100590342B1 (ko) 2001-03-28 2006-06-15 쉐링 코포레이션 아제티딘온 중간체 화합물의 에난티오-선택적 합성법
CA2460344A1 (en) * 2001-09-21 2003-04-03 Schering Corporation Methods for treating or preventing vascular inflammation using sterol absorption inhibitor(s)
WO2003026643A2 (en) * 2001-09-21 2003-04-03 Schering Corporation Treatment of xanthoma with azetidinone derivatives as sterol absorption inhibitors
WO2003043624A1 (en) 2001-11-16 2003-05-30 Bristol-Myers Squibb Company Dual inhibitors of adipocyte fatty acid binding protein and keratinocyte fatty acid binding protein
US20030204096A1 (en) * 2002-03-25 2003-10-30 Schering Corporation Enantioselective synthesis of azetidinone intermediate compounds
GB0215579D0 (en) * 2002-07-05 2002-08-14 Astrazeneca Ab Chemical compounds
US7135556B2 (en) * 2002-07-19 2006-11-14 Schering Corporation NPC1L1 (NPC3) and methods of use thereof
AR040588A1 (es) * 2002-07-26 2005-04-13 Schering Corp Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
WO2004041210A2 (en) 2002-11-05 2004-05-21 Smithkline Beecham Corporation Antibacterial agents
MXPA05009502A (es) * 2003-03-07 2005-10-18 Schering Corp Compuestos de azetidinona sustituidos, formulaciones y usos de los mismos para el tratamiento de hipercolesterolemia.
EP1810971B1 (de) * 2003-03-07 2013-12-25 Merck Sharp & Dohme Corp. Substituierte Azetidinon-Derivate, deren pharmazeutische Formulierungen und deren Verwendung zur Behandlung von Hypercholesterolemia
MXPA05009501A (es) * 2003-03-07 2005-10-18 Schering Corp Compuestos de azetidinona sustituidos, formulaciones y usos de los mismos para el tratamiento de hipercolesterolemia.
CA2517571C (en) * 2003-03-07 2011-07-05 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
JP2005015434A (ja) * 2003-06-27 2005-01-20 Kotobuki Seiyaku Kk 血清コレステロール低下剤或はアテローム性硬化症の予防又は治療剤
US20060089374A1 (en) * 2003-07-17 2006-04-27 Glenn Cornett Enantiomeric compositions of cicletanine, alone and in combination with other agents, for the treatment of disease
WO2005021039A1 (en) * 2003-08-29 2005-03-10 Cotherix, Inc. Combination of cicletanine and an oral antidiabetic and/or blood lipid-lowering agent for treating diabetes and metabolic syndrome
US7371759B2 (en) 2003-09-25 2008-05-13 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
EP1918000A2 (de) 2003-11-05 2008-05-07 Schering Corporation Verbindungen aus lipidverändernden Wirkstoffen und substituierten Azetidinonen und Behandlungen für Gefäßzustände
US7420059B2 (en) 2003-11-20 2008-09-02 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
CN100471835C (zh) * 2003-12-23 2009-03-25 默克公司 抗高胆固醇血症化合物
GB0329778D0 (en) * 2003-12-23 2004-01-28 Astrazeneca Ab Chemical compounds
CA2550215A1 (en) * 2003-12-23 2005-07-07 Astrazeneca Ab Diphenylazetidinone derivates possessing cholesterol absorption inhibitory activity
CA2553769C (en) * 2004-01-16 2011-01-04 Merck & Co., Inc. Npc1l1 (npc3) and methods of identifying ligands thereof
AR049655A1 (es) * 2004-07-01 2006-08-23 Schering Corp Antagonistas de nk1
US7572805B2 (en) 2004-07-14 2009-08-11 Bristol-Myers Squibb Company Pyrrolo(oxo)isoquinolines as 5HT ligands
US20060046996A1 (en) * 2004-08-31 2006-03-02 Kowa Co., Ltd. Method for treating hyperlipidemia
US20060154959A1 (en) * 2005-01-13 2006-07-13 Navitas Pharma Combination therapies of cicletanine and carvedilol
MX2007003732A (es) * 2004-09-29 2007-04-23 Schering Corp Combinaciones de azetidononas sustituidas y antagonistas de receptor de canabinoide 1.
US7517991B2 (en) 2004-10-12 2009-04-14 Bristol-Myers Squibb Company N-sulfonylpiperidine cannabinoid receptor 1 antagonists
WO2006076597A1 (en) 2005-01-12 2006-07-20 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid receptor modulators
US7361766B2 (en) 2005-01-12 2008-04-22 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid receptor modulators
US7314882B2 (en) 2005-01-12 2008-01-01 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid receptor modulators
US20070141174A1 (en) * 2005-01-13 2007-06-21 Navitas Pharma, Inc. Enantiomeric compositions of cicletanine, in combination with other agents, for the treatment of hypertension
US20080096915A1 (en) * 2005-01-13 2008-04-24 Greenberg Traurig LLP Compositions for the treatment of metabolic disorders
US20060160850A1 (en) 2005-01-18 2006-07-20 Chongqing Sun Bicyclic heterocycles as cannabinoid receptor modulators
ES2319461T3 (es) 2005-02-10 2009-05-07 Bristol-Myers Squibb Company Dihidroquinazolinonas como moduladores de 5ht.
US7632837B2 (en) 2005-06-17 2009-12-15 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid-1 receptor modulators
US7317012B2 (en) 2005-06-17 2008-01-08 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoind-1 receptor modulators
TW200726765A (en) 2005-06-17 2007-07-16 Bristol Myers Squibb Co Triazolopyridine cannabinoid receptor 1 antagonists
US7629342B2 (en) 2005-06-17 2009-12-08 Bristol-Myers Squibb Company Azabicyclic heterocycles as cannabinoid receptor modulators
US7452892B2 (en) 2005-06-17 2008-11-18 Bristol-Myers Squibb Company Triazolopyrimidine cannabinoid receptor 1 antagonists
UY29607A1 (es) * 2005-06-20 2007-01-31 Astrazeneca Ab Compuestos quimicos
CN101243072A (zh) * 2005-06-20 2008-08-13 先灵公司 用作组胺h3拮抗剂的哌啶衍生物
SA06270191B1 (ar) * 2005-06-22 2010-03-29 استرازينيكا ايه بي مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم
AR057383A1 (es) * 2005-06-22 2007-12-05 Astrazeneca Ab Compuestos quimicos derivados de 2-azetidinona, formulacion farmaceutica y un proceso de preparacion del compuesto
MY148538A (en) * 2005-06-22 2013-04-30 Astrazeneca Ab Novel 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions
AR054482A1 (es) * 2005-06-22 2007-06-27 Astrazeneca Ab Derivados de azetidinona para el tratamiento de hiperlipidemias
AR057380A1 (es) * 2005-06-22 2007-11-28 Astrazeneca Ab Compuestos quimicos derivados de 2-azetidinona y uso terapeutico de los mismos
US7795436B2 (en) 2005-08-24 2010-09-14 Bristol-Myers Squibb Company Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists
US8618115B2 (en) 2005-10-26 2013-12-31 Bristol-Myers Squibb Company Substituted thieno[3,2-d]pyrimidinones as MCHR1 antagonists and methods for using them
US20070105817A1 (en) * 2005-11-09 2007-05-10 Jim Page Use of cicletanine and other furopyridines for treatment of systolic-predominant hypertension, isolated systolic hypertension, elevated pulse pressure, and general hypertension
EP1962835A2 (de) * 2005-12-21 2008-09-03 Schering Corporation Behandlung nicht alkoholinduzierter fettleber mittels cholesterinsenkenden mitteln und/oder h3-rezeptor-antagonisten oder -inversagonisten
US7553836B2 (en) 2006-02-06 2009-06-30 Bristol-Myers Squibb Company Melanin concentrating hormone receptor-1 antagonists
WO2007100807A2 (en) * 2006-02-24 2007-09-07 Schering Corporation Npc1l1 orthologues
TW200811098A (en) 2006-04-27 2008-03-01 Astrazeneca Ab Chemical compounds
US20070275052A1 (en) * 2006-05-24 2007-11-29 Glenmark Pharmaceuticals Limited Pharmaceutical compositions containing sterol inhibitors
WO2008030382A1 (en) * 2006-09-05 2008-03-13 Schering Corporation Pharmaceutical combinations for lipid management and in the treatment of atherosclerosis and hepatic steatosis
CA2674367A1 (en) * 2007-01-03 2008-07-17 Glenn V. Cornett Cicletanine and pkc inhibitors in the treatment of pulmonary and cardiac disorders
US20090011994A1 (en) 2007-07-06 2009-01-08 Bristol-Myers Squibb Company Non-basic melanin concentrating hormone receptor-1 antagonists and methods
PE20091928A1 (es) 2008-05-29 2009-12-31 Bristol Myers Squibb Co Tienopirimidinas hidroxisustituidas como antagonistas de receptor-1 de hormona concentradora de melanina no basicos
WO2010021681A2 (en) * 2008-08-18 2010-02-25 Combinatorx (Singapore) Pte. Ltd. Compositions and methods for treatment of viral diseases
CA2756786A1 (en) 2009-03-27 2010-09-30 Bristol-Myers Squibb Company Methods for preventing major adverse cardiovascular events with dpp-iv inhibitors
EP2892897A1 (de) 2012-09-05 2015-07-15 Bristol-Myers Squibb Company Pyrrolon- oder pyrrolidinon-antagonisten des melaninkonzentrierenden hormonrezeptor-1
EP2892896B1 (de) 2012-09-05 2016-06-29 Bristol-Myers Squibb Company Pyrrolon- oder pyrrolidinon-antagonisten des melaninkonzentrierenden hormonrezeptor-1
CR20210029A (es) 2018-07-19 2021-02-26 Astrazeneca Ab MÉTODOS DE TRATAMIENTO DE HFpEF EMPLEANDO DAPAGLIFLOZINA Y COMPOSICIONES QUE COMPRENDEN LA MISMA
TW202317534A (zh) 2021-06-16 2023-05-01 美商西建公司 用於治療神經退化性疾病之含羧酸吖丁啶基化合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4680391A (en) * 1983-12-01 1987-07-14 Merck & Co., Inc. Substituted azetidinones as anti-inflammatory and antidegenerative agents
US4983597A (en) * 1989-08-31 1991-01-08 Merck & Co., Inc. Beta-lactams as anticholesterolemic agents
US5120729A (en) * 1990-06-20 1992-06-09 Merck & Co., Inc. Beta-lactams as antihypercholesterolemics
US5085473A (en) * 1990-10-09 1992-02-04 Yuhe Yang Air actuated car curtain device
TW223059B (de) 1991-07-23 1994-05-01 Schering Corp
PL2807099T3 (pl) 2012-01-26 2017-08-31 Intralot S.A. - Integrated Lottery Systems And Services Sposoby i układy do wydawania

Also Published As

Publication number Publication date
LV10919A (lv) 1995-12-20
DE69323213T2 (de) 1999-07-08
MY109538A (en) 1997-02-28
TW319698B (de) 1997-11-11
LTIP1514A (en) 1994-10-25
SK281173B6 (sk) 2000-12-11
SK78395A3 (en) 1996-05-08
FI952916A (fi) 1995-06-14
NO952529L (no) 1995-06-23
CA2152351A1 (en) 1994-07-07
AU5872094A (en) 1994-07-19
YU49060B (sh) 2003-08-29
KR100306936B1 (ko) 2001-11-30
LV10919B (en) 1996-04-20
LT3300B (en) 1995-06-26
CZ287125B6 (en) 2000-09-13
CN1095591A (zh) 1994-11-30
CA2152351C (en) 2009-09-22
CN1090479C (zh) 2002-09-11
JPH08505141A (ja) 1996-06-04
ZA939552B (en) 1994-10-12
PL309636A1 (en) 1995-10-30
HUT72081A (en) 1996-03-28
HU9501854D0 (en) 1995-08-28
NO311325B1 (no) 2001-11-19
PL174128B1 (pl) 1998-06-30
JP3992728B2 (ja) 2007-10-17
ES2128552T3 (es) 1999-05-16
CZ164395A3 (en) 1996-03-13
SI9300677A (en) 1994-09-30
HRP931515B1 (en) 2000-02-29
NZ259790A (en) 1997-02-24
EP0675714B1 (de) 1999-01-20
SG45147A1 (en) 1998-01-16
YU80293A (sh) 1997-12-05
NO952529D0 (no) 1995-06-23
AU680864B2 (en) 1997-08-14
GR3029405T3 (en) 1999-05-28
HU221724B1 (hu) 2002-12-28
ATE175872T1 (de) 1999-02-15
HRP931515A2 (en) 1996-12-31
US5661145A (en) 1997-08-26
FI952916A0 (fi) 1995-06-14
EE03383B1 (et) 2001-04-16
IL108112A (en) 1999-11-30
EP0675714A1 (de) 1995-10-11
WO1994014433A1 (en) 1994-07-07
DK0675714T3 (da) 1999-09-13
EE9400341A (et) 1996-04-15
MX9308053A (es) 1994-06-30
IL108112A0 (en) 1994-04-12

Similar Documents

Publication Publication Date Title
ATE175872T1 (de) Kombination eines hemmers der cholesterin- biosynthese und eines beta-laktamischem hemmers der cholesterinabsorption
AU2483000A (en) Treatment of asthma with mek inhibitors
BG103190A (en) Substituted pyrimidine derivatives and their pharmaceutical application
AU3451797A (en) Compositions for the treatment of peripheral neuropathies containing antidepressants and/or monoamine oxidase inhibitors and/or vitamin b12 and/or precursors or inducers of a neurotransmitter
EP0646007A4 (de)
BG101937A (en) Pharmaceutical compositions comprising monoamine oxidase b inhibitors
DE69332567T2 (de) Inhibitoren von metazoan-parasit-proteasen
HUT70979A (en) Use of cytochrome p450 inhibitors for inhibiting the metabolism of nitrogen substituted acridine
HUT73231A (en) Pharmaceutical compositions with 17-beta-monosubstituted-carbamoyl-4-aza-5-alpha-androst-1-en-3-ones for treatment of chronic prostatitis
AU6846996A (en) Quinazolinone-containing pharmaceutical compositions for prevention of neovascularization and for treating human malignancies
ATE316385T1 (de) Zusammensetzungen zur behandlung und vorbeugung von atherosklerose
DE69717277D1 (en) Imidazopyridine
AU5625194A (en) Rectal flunisolide compositions for treating inflammatory intestinal disorders
UA41376C2 (uk) ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ ТА СПОСІБ ЛІКУВАННЯ АНДРОГЕННОЇ АЛОПЕЦІЇ ІНГІБІТОРАМИ 5-<font face="Symbol">a</font>-РЕДУКТАЗИ

Legal Events

Date Code Title Description
8364 No opposition during term of opposition